POWEL HBROWNPOWEL H BROWN9636BROWN, POWEL HProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25456381Brewster AM, Chavez-MacGregor M, Brown PThe Lancet. OncologyEpidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014 Dec; 15(13):e625-e634.Lancet Oncol2014-11-24T00:00:002014Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.1155 Pressler StHouston77030-3721TXAuthorship 1670441Authorship 1671501Authorship 1677714Authorship 1679207Authorship 1690974Authorship 16926812Authorship 1693041Authorship 16942712Authorship 1698854Authorship 1699064Authorship 17056011Authorship 1706324Authorship 1714682Authorship 17155710Authorship 1717703Authorship 17178711Authorship 17191311Authorship 1720924Authorship 17292414Authorship 1731856Authorship 1734921Authorship 1735673Authorship 1740355Authorship 1748221Authorship 1750446Authorship 1751732Authorship 1753412Authorship 1755162Authorship 1756324Authorship 1759303Authorship 17602612Authorship 1763805Authorship 1765336Authorship 1768612Authorship 1769144Authorship 17712912Authorship 1778827Authorship 1779685Authorship 1781652Authorship 17822917Authorship 1784137Authorship 1785056Authorship 17865910Authorship 1789938Authorship 1801951Authorship 18191412Authorship 1819172Authorship 1821001Authorship 1823707Authorship 1828182Authorship 1828592Authorship 1828924Authorship 18350415Authorship 1838482Authorship 1839807Authorship 1843952Authorship 18439712Authorship 18446710Authorship 1847539Authorship 1852272Authorship 18578210Authorship 1858181Authorship 1878776Authorship 1881642Authorship 1884574Authorship 1886126Authorship 18919310Authorship 1895123Authorship 1906112Authorship 1906274Authorship 19068114Authorship 1908442Authorship 1911915Authorship 19150010Authorship 1942881Authorship 195898108455942Brown PH, Alani R, Preis LH, Szabo E, Birrer MJOncogeneSuppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene. 1993 Apr; 8(4):877-86.Oncogene1993-04-01T00:00:001993Suppression of oncogene-induced transformation by a deletion mutant of c-jun.9230221Smith LM, Birrer MJ, Stampfer MR, Brown PHCancer researchBreast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res. 1997 Jul 15; 57(14):3046-54.Cancer Res1997-07-15T00:00:001997Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells.12509137Kavanaugh CJ, Desai KV, Calvo A, Brown PH, Couldrey C, Lubet R, Green JETransgenic researchPre-clinical applications of transgenic mouse mammary cancer models. Transgenic Res. 2002 Dec; 11(6):617-33.Transgenic Res2002-12-01T00:00:002002Pre-clinical applications of transgenic mouse mammary cancer models.12783921Wu K, Brown PJournal of the National Cancer InstituteIs low-dose tamoxifen useful for the treatment and prevention of breast cancer? J Natl Cancer Inst. 2003 Jun 04; 95(11):766-7.J Natl Cancer Inst2003-06-04T00:00:002003Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?19470930Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM, American Society of Clinical OncologyJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009 Jul 01; 27(19):3235-58.J Clin Oncol2009-05-26T00:00:002009American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.Breast Medical OncologyClinical Cancer PreventionLeukemiaMolecular & Cellular OncologySystems BiologyMD AndersonMIEN-CHIEHUNGMIEN-CHIE HUNG8427HUNG, MIEN-CHIEProfessor3.248950.00209061503research areas1.600730.0083292541coauthor of77.732916.449660similar to11143selected publicationsQIANGSHENQIANG SHEN9638SHEN, QIANGAssistant ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorKELLY KHUNTKELLY K HUNT8555HUNT, KELLY KProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorABENAABREWSTERABENAA BREWSTER8999BREWSTER, ABENAAProfessorAMAN UBUZDARAMAN U BUZDAR8609BUZDAR, AMAN UProfessorAuthorship 2121623Authorship 2127722Authorship 2131851Authorship 2145395Authorship 2155893Authorship 2167545Authorship 2172686Authorship 2174804Authorship 2209152Authorship 221672Authorship 2261149Authorship 23363041751404Szabo E, Preis LH, Brown PH, Birrer MJCell growth & differentiation : the molecular biology journal of the American Association for Cancer ResearchThe role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation. Cell Growth Differ. 1991 Oct; 2(10):475-82.Cell Growth Differ1991-10-01T00:00:001991The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation.3334050Ponzio NM, Brown PH, Thorbecke GJInternational reviews of immunologyHost-tumor interactions in the SJL lymphoma model. Int Rev Immunol. 1986 Jul; 1(3-4):273-301.Int Rev Immunol1986-07-01T00:00:001986Host-tumor interactions in the SJL lymphoma model.3527449Brown PH, Coico RF, Thorbecke GJCellular immunologyProliferative responses of T cells from SJL----F1 and F1----SJL bone marrow chimeras to SJL lymphoma cells. Cell Immunol. 1986 Mar; 98(1):18-27.Cell Immunol1986-03-01T00:00:001986Proliferative responses of T cells from SJL----F1 and F1----SJL bone marrow chimeras to SJL lymphoma cells.8380133Mulshine JL, Treston AM, Brown PH, Birrer MJ, Shaw GLChestInitiators and promoters of lung cancer. Chest. 1993 Jan; 103(1 Suppl):4S-11S.Chest1993-01-01T00:00:001993Initiators and promoters of lung cancer.8597534Chen TK, Smith LM, Gebhardt DK, Birrer MJ, Brown PHMolecular carcinogenesisActivation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog. 1996 Mar; 15(3):215-26.Mol Carcinog1996-03-01T00:00:001996Activation and inhibition of the AP-1 complex in human breast cancer cells.9254885Zhao B, Yu W, Qian M, Simmons-Menchaca M, Brown P, Birrer MJ, Sanders BG, Kline KMolecular carcinogenesisInvolvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Mol Carcinog. 1997 Jul; 19(3):180-90.Mol Carcinog1997-07-01T00:00:001997Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells.9726817Yu W, Simmons-Menchaca M, You H, Brown P, Birrer MJ, Sanders BG, Kline KMolecular carcinogenesisRRR-alpha-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog. 1998 Aug; 22(4):247-57.Mol Carcinog1998-08-01T00:00:001998RRR-alpha-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells.10573118Yang L, Munoz-Medellin D, Kim HT, Ostrowski J, Reczek P, Brown PHBreast cancer research and treatmentRetinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res Treat. 1999 Aug; 56(3):277-91.Breast Cancer Res Treat1999-08-01T00:00:001999Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression.14587859Ip C, Brown PJournal of mammary gland biology and neoplasiaPrevention of breast cancer--present reality and future promise. J Mammary Gland Biol Neoplasia. 2003 Jan; 8(1):1-3.J Mammary Gland Biol Neoplasia2003-01-01T00:00:002003Prevention of breast cancer--present reality and future promise.15126613Campiglio M, Normanno N, M?nard SJournal of the National Cancer InstituteRe: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2004 May 05; 96(9):715; author reply 715-6.J Natl Cancer Inst2004-05-05T00:00:002004Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.19075281Zon RT, Goss E, Vogel VG, Chlebowski RT, Jatoi I, Robson ME, Wollins DS, Garber JE, Brown P, Kramer BS, American Society of Clinical OncologyJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol. 2009 Feb 20; 27(6):986-93.J Clin Oncol2008-12-15T00:00:002008American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.23835710Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG, Wade JL, Lippman SMJournal of clinical oncology : official journal of the American Society of Clinical OncologyUse of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013 Aug 10; 31(23):2942-62.J Clin Oncol2013-07-08T00:00:002013Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.Authorship 2357669Authorship 2364102Authorship 2376341Authorship 2380519Authorship 2381081Authorship 2381621Authorship 2386582Authorship 2387552Authorship 2420312Authorship 2440004Authorship 2520182Authorship 254204171389694Birrer MJ, Alani R, Cuttitta F, Preis LH, Sabich AL, Sanders DA, Siegfried JM, Szabo E, Brown PHJournal of the National Cancer Institute. MonographsEarly events in the neoplastic transformation of respiratory epithelium. J Natl Cancer Inst Monogr. 1992; (13):31-7.J Natl Cancer Inst Monogr1992-01-01T00:00:001992Early events in the neoplastic transformation of respiratory epithelium.1469899Mulshine JL, Linnoila RI, Treston AM, Scott FM, Quinn K, Avis I, Shaw GL, Jensen SM, Brown P, Birrer MJJournal of cellular biochemistry. SupplementCandidate biomarkers for application as intermediate end points of lung carcinogenesis. J Cell Biochem Suppl. 1992; 16G:183-6.J Cell Biochem Suppl1992-01-01T00:00:001992Candidate biomarkers for application as intermediate end points of lung carcinogenesis.1944289Alani R, Brown P, Bin?truy B, Dosaka H, Rosenberg RK, Angel P, Karin M, Birrer MJMolecular and cellular biologyThe transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol. 1991 Dec; 11(12):6286-95.Mol Cell Biol1991-12-01T00:00:001991The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells.3900211Brown PH, Thorbecke GJJournal of immunology (Baltimore, Md. : 1950)Characterization of the molecules on SJL/J lymphomas which stimulate syngeneic T cells. J Immunol. 1985 Nov; 135(5):3572-80.J Immunol1985-11-01T00:00:001985Characterization of the molecules on SJL/J lymphomas which stimulate syngeneic T cells.6226603Brown PH, Mathis D, Cone RE, Jones PP, Ponzio NM, Thorbecke GJImmunogeneticsProperties of reticulum cell sarcomas in SJL/J mice. VIII. Prominent role of RCS cell I-A antigens in the stimulation of syngeneic T cells. Immunogenetics. 1983; 18(4):399-413.Immunogenetics1983-01-01T00:00:001983Properties of reticulum cell sarcomas in SJL/J mice. VIII. Prominent role of RCS cell I-A antigens in the stimulation of syngeneic T cells.7600036Battey JF, Brown PH, Gritz ER, Hong WK, Johnson BE, Karp DD, Mulshine JL, Shaw GL, Shopland DR, Sunday MELung cancer (Amsterdam, Netherlands)Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop. Lung Cancer. 1995 Mar; 12(1-2):91-103.Lung Cancer1995-03-01T00:00:001995Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop.8108121Brown PH, Chen TK, Birrer MJOncogeneMechanism of action of a dominant-negative mutant of c-Jun. Oncogene. 1994 Mar; 9(3):791-9.Oncogene1994-03-01T00:00:001994Mechanism of action of a dominant-negative mutant of c-Jun.8649795Kim S, Brown PH, Birrer MJOncogeneThe inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor. Oncogene. 1996 Mar 07; 12(5):1043-53.Oncogene1996-03-07T00:00:001996The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.10547388Lippman SM, Brown PHJournal of the National Cancer InstituteTamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst. 1999 Nov 03; 91(21):1809-19.J Natl Cancer Inst1999-11-03T00:00:001999Tamoxifen prevention of breast cancer: an instance of the fingerpost.11753686Yang L, Ostrowski J, Reczek P, Brown POncogeneThe retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. Oncogene. 2001 Nov 29; 20(55):8025-35.Oncogene2001-11-29T00:00:002001The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest.19001596Speers C, Brown PJournal of the National Cancer InstituteBreast cancer prevention using calcium and vitamin D: a bright future? J Natl Cancer Inst. 2008 Nov 19; 100(22):1562-4.J Natl Cancer Inst2008-11-11T00:00:002008Breast cancer prevention using calcium and vitamin D: a bright future?20921021Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P, kConFab, Moore R, Southey MC, Hopper JL, Garber JE, Huntsman DGJournal of medical geneticsGermline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. J Med Genet. 2011 Jan; 48(1):64-8.J Med Genet2010-10-04T00:00:002010Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.Authorship 2632542Authorship 2645735Authorship 267718122413126DeKruyff RH, Brown PH, Thorbecke GJ, Ponzio NMJournal of immunology (Baltimore, Md. : 1950)Characterization of SJL T cell clones responsive to syngeneic lymphoma (RCS): RCS-specific clones are stimulated by activated B cells. J Immunol. 1985 Nov; 135(5):3581-6.J Immunol1985-11-01T00:00:001985Characterization of SJL T cell clones responsive to syngeneic lymphoma (RCS): RCS-specific clones are stimulated by activated B cells.9377582Yang L, Kim HT, Munoz-Medellin D, Reddy P, Brown PHCancer researchInduction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res. 1997 Oct 15; 57(20):4652-61.Cancer Res1997-10-15T00:00:001997Induction of retinoid resistance in breast cancer cells by overexpression of cJun.17020999Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MBClinical cancer research : an official journal of the American Association for Cancer ResearchThe combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res. 2006 Oct 01; 12(19):5902-9.Clin Cancer Res2006-10-01T00:00:002006The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.Authorship 2757172Authorship 27597121562996Birrer MJ, Brown PHCancer researchApplication of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res. 1992 May 01; 52(9 Suppl):2658s-2664s.Cancer Res1992-05-01T00:00:001992Application of molecular genetics to the early diagnosis and screening of lung cancer.8243888Kurie JM, Brown P, Salk E, Scheinberg D, Birrer M, Deutsch P, Dmitrovsky EDifferentiation; research in biological diversityCooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. Differentiation. 1993 Sep; 54(2):115-22.Differentiation1993-09-01T00:00:001993Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation.10557095Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJOncogenecJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70.Oncogene1999-10-28T00:00:001999cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.10705921Yang LM, Tin-U C, Wu K, Brown PJournal of mammary gland biology and neoplasiaRole of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia. 1999 Oct; 4(4):377-88.J Mammary Gland Biol Neoplasia1999-10-01T00:00:001999Role of retinoid receptors in the prevention and treatment of breast cancer.Authorship 301742126063617Haricharan S, Brown PProceedings of the National Academy of Sciences of the United States of AmericaTLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):E3216-25.Proc Natl Acad Sci U S A2015-06-10T00:00:002015TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth.26075823Zhao J, Zhao D, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PHThe Journal of clinical investigationDeath-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest. 2015 Jul 01; 125(7):2707-20.J Clin Invest2015-06-15T00:00:002015Death-associated protein kinase 1 promotes growth of p53-mutant cancers.26675741Brown PThe oncologistWomen's Expectations for Breast Cancer Prevention and Early Detection: High Expectations Can Be Achieved. Oncologist. 2016 Jan; 21(1):4-6.Oncologist2015-12-16T00:00:002015Women's Expectations for Breast Cancer Prevention and Early Detection: High Expectations Can Be Achieved.10999763Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PHClinical cancer research : an official journal of the American Association for Cancer Research9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res. 2000 Sep; 6(9):3696-704.Clin Cancer Res2000-09-01T00:00:0020009-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.8853897Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJCell growth & differentiation : the molecular biology journal of the American Association for Cancer ResearchDominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies. Cell Growth Differ. 1996 Aug; 7(8):1013-21.Cell Growth Differ1996-08-01T00:00:001996Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies.11933076You H, Yu W, Munoz-Medellin D, Brown PH, Sanders BG, Kline KMolecular carcinogenesisRole of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells. Mol Carcinog. 2002 Apr; 33(4):228-36.Mol Carcinog2002-04-01T00:00:002002Role of extracellular signal-regulated kinase pathway in RRR-alpha-tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells.12010861Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PHCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologySuppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74.Cancer Epidemiol Biomarkers Prev2002-05-01T00:00:002002Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.12438218Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, Brown PHCancer researchThe retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002 Nov 15; 62(22):6376-80.Cancer Res2002-11-15T00:00:002002The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.12927029Schiff R, Chamness GC, Brown PHBreast cancer research : BCRAdvances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). Breast Cancer Res. 2003; 5(5):228-31.Breast Cancer Res2003-07-28T00:00:002003Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).74Professor10Assistant Professor27Clinical Assistant Professor78Professor Emeritus11106684Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CKJournal of the National Cancer InstituteOxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.J Natl Cancer Inst2000-12-06T00:00:002000Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.15687551Osborne CK, Elledge RM, Brown PH, Hilsenbeck SGBreast diseaseBRCA1 in clinical breast cancer. Breast Dis. 1998 Apr; 10(1-2):77-88.Breast Dis1998-04-01T00:00:001998BRCA1 in clinical breast cancer.15725110Brown PThe breast journalRisk assessment: controversies and management of moderate- to high-risk individuals. Breast J. 2005 Mar-Apr; 11 Suppl 1:S11-9.Breast J2005-03-01T00:00:002005Risk assessment: controversies and management of moderate- to high-risk individuals.Breast Surgical Oncology11420689Ludes-Meyers JH, Liu Y, Mu?oz-Medellin D, Hilsenbeck SG, Brown PHOncogeneAP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17; 20(22):2771-80.Oncogene2001-05-17T00:00:002001AP-1 blockade inhibits the growth of normal and malignant breast cells.12000762Shah S, Pishvaian MJ, Easwaran V, Brown PH, Byers SWThe Journal of biological chemistryThe role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J Biol Chem. 2002 Jul 12; 277(28):25313-22.J Biol Chem2002-05-08T00:00:002002The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation.16678816Shen Q, Zhang Y, Uray IP, Hill JL, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, Brown PHDevelopmental biologyThe AP-1 transcription factor regulates postnatal mammary gland development. Dev Biol. 2006 Jul 15; 295(2):589-603.Dev Biol2006-04-04T00:00:002006The AP-1 transcription factor regulates postnatal mammary gland development.12400010Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PHOncogeneInhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.Oncogene2002-10-31T00:00:002002Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.17126817Duan L, Sterba K, Kolomeichuk S, Kim H, Brown PH, Chambers TCBiochemical pharmacologyInducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem Pharmacol. 2007 Feb 15; 73(4):481-90.Biochem Pharmacol2006-10-29T00:00:002006Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest.17493263Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CMGenome biologyIdentification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007; 8(5):R76.Genome Biol2007-01-01T00:00:002007Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.17825481DeNardo DG, Cuba VL, Kim H, Wu K, Lee AV, Brown PHMolecular and cellular endocrinologyEstrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol. 2007 Oct 15; 277(1-2):13-25.Mol Cell Endocrinol2007-07-19T00:00:002007Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth.19138935Shen Q, Uray IP, Li Y, Zhang Y, Hill J, Xu XC, Young MR, Gunther EJ, Hilsenbeck SG, Colburn NH, Chodosh LA, Brown PHCancer prevention research (Philadelphia, Pa.)Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila). 2008 Jun; 1(1):45-55.Cancer Prev Res (Phila)2008-03-31T00:00:002008Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors.15899070Kalidas M, Brown PClinical breast cancerAromatase inhibitors for the treatment and prevention of breast cancer. Clin Breast Cancer. 2005 Apr; 6(1):27-37.Clin Breast Cancer2005-04-01T00:00:002005Aromatase inhibitors for the treatment and prevention of breast cancer.15941935Brown PH, Rashid ACancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyCancer prevention: the importance of accurate risk assessment. Cancer Epidemiol Biomarkers Prev. 2005 Jun; 14(6):1357-8.Cancer Epidemiol Biomarkers Prev2005-06-01T00:00:002005Cancer prevention: the importance of accurate risk assessment.15514030DeNardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PHMolecular endocrinology (Baltimore, Md.)Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol. 2005 Feb; 19(2):362-78.Mol Endocrinol2004-10-28T00:00:002004Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes.15535853Allred DC, Brown P, Medina DBreast cancer research : BCRThe origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004; 6(6):240-5.Breast Cancer Res2004-09-22T00:00:002004The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.15572750Kalidas M, Hilsenbeck S, Brown PJournal of the National Cancer InstituteDefining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst. 2004 Dec 01; 96(23):1731-3.J Natl Cancer Inst2004-12-01T00:00:002004Defining the role of raloxifene for the prevention of breast cancer.21541704Casa AJ, Potter AS, Malik S, Lazard Z, Kuiatse I, Kim HT, Tsimelzon A, Creighton CJ, Hilsenbeck SG, Brown PH, Oesterreich S, Lee AVBreast cancer research and treatmentEstrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Res Treat. 2012 Feb; 132(1):61-73.Breast Cancer Res Treat2011-05-04T00:00:002011Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth.Authorship 3747722Authorship 3747737Authorship 37477410Authorship 3747753Authorship 3748421215833886Medina D, Kittrell FS, Hill J, Shepard A, Thordarson G, Brown PCancer researchTamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis. Cancer Res. 2005 Apr 15; 65(8):3493-6.Cancer Res2005-04-15T00:00:002005Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis.15888345Shen Q, Brown PHMutation researchTransgenic mouse models for the prevention of breast cancer. Mutat Res. 2005 Aug 25; 576(1-2):93-110.Mutat Res2005-08-25T00:00:002005Transgenic mouse models for the prevention of breast cancer.16273314Wu K, DuPr? E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW, Brown PHBreast cancer research and treatmentReceptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res Treat. 2006 Mar; 96(2):147-57.Breast Cancer Res Treat2005-11-05T00:00:002005Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade.17178900Kim HT, Kong G, Denardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PHCancer researchIdentification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. Cancer Res. 2006 Dec 15; 66(24):12009-18.Cancer Res2006-12-15T00:00:002006Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays.17684123Brown PHCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyChemoprevention clinical trials: it is time to turn success into progress. Cancer Epidemiol Biomarkers Prev. 2007 Aug; 16(8):1531-2.Cancer Epidemiol Biomarkers Prev2007-08-01T00:00:002007Chemoprevention clinical trials: it is time to turn success into progress.17107283Uray IP, Brown PHExpert opinion on investigational drugsPrevention of breast cancer: current state of the science and future opportunities. Expert Opin Investig Drugs. 2006 Dec; 15(12):1583-600.Expert Opin Investig Drugs2006-12-01T00:00:002006Prevention of breast cancer: current state of the science and future opportunities.17415091Li Y, Brown PHEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)Translational approaches for the prevention of estrogen receptor-negative breast cancer. Eur J Cancer Prev. 2007 Jun; 16(3):203-15.Eur J Cancer Prev2007-06-01T00:00:002007Translational approaches for the prevention of estrogen receptor-negative breast cancer.17637753Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PHOncogeneThe AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors. Oncogene. 2008 Jan 10; 27(3):366-77.Oncogene2007-07-16T00:00:002007The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors.18990728Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM, CEBP Senior Editors and CaPR Deputy and Senior EditorsCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyCancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):2903-5.Cancer Epidemiol Biomarkers Prev2008-11-01T00:00:002008Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal.19138951Abate-Shen C, Brown PH, Colburn NH, Gerner EW, Green JE, Lipkin M, Nelson WG, Threadgill DCancer prevention research (Philadelphia, Pa.)The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res (Phila). 2008 Aug; 1(3):161-6.Cancer Prev Res (Phila)2008-08-01T00:00:002008The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges.19138958Brown PH, Subbaramaiah K, Salmon AP, Baker R, Newman RA, Yang P, Zhou XK, Bissonnette RP, Dannenberg AJ, Howe LRCancer prevention research (Philadelphia, Pa.)Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid. Cancer Prev Res (Phila). 2008 Aug; 1(3):208-14.Cancer Prev Res (Phila)2008-08-01T00:00:002008Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.19138984Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM, CEBP Senior Editors and CaPR Deputy and Senior EditorsCancer prevention research (Philadelphia, Pa.)Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila). 2008 Nov; 1(6):393-5.Cancer Prev Res (Phila)2008-11-01T00:00:002008Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal.19141783Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, Kim HT, Gilmer TM, Sexton KR, Hilsenbeck SG, Osborne CK, Brown PHJournal of the National Cancer InstituteEffect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst. 2009 Jan 21; 101(2):107-13.J Natl Cancer Inst2009-01-13T00:00:002009Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.19174577Medina D, Kittrell F, Hill J, Zhang Y, Hilsenbeck SG, Bissonette R, Brown PHCancer prevention research (Philadelphia, Pa.)Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer Prev Res (Phila). 2009 Feb; 2(2):168-74.Cancer Prev Res (Phila)2009-01-27T00:00:002009Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.19213564Li Y, Brown PHRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancerPrevention of ER-negative breast cancer. Recent Results Cancer Res. 2009; 181:121-34.Recent Results Cancer Res2009-01-01T00:00:002009Prevention of ER-negative breast cancer.19241157Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JCBreast cancer research and treatmentDecreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010 Jan; 119(2):305-14.Breast Cancer Res Treat2009-02-25T00:00:002009Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density.19410194Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun MThe Lancet. OncologyAspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009 May; 10(5):501-7.Lancet Oncol2009-05-01T00:00:002009Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement.19808870Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown PClinical cancer research : an official journal of the American Association for Cancer ResearchIdentification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res. 2009 Oct 15; 15(20):6327-40.Clin Cancer Res2009-10-06T00:00:002009Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.19920204Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, Brown PHCancer researchInhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res. 2009 Dec 01; 69(23):8853-61.Cancer Res2009-11-17T00:00:002009Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells.21441069Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina HThe Lancet. OncologyPreventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011 May; 12(5):496-503.Lancet Oncol2011-05-01T00:00:002011Preventive therapy for breast cancer: a consensus statement.21816844Howe LR, Brown PHCancer prevention research (Philadelphia, Pa.)Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila). 2011 Aug; 4(8):1149-57.Cancer Prev Res (Phila)2011-08-01T00:00:002011Targeting the HER/EGFR/ErbB family to prevent breast cancer.21867536Dearth RK, Kuiatse I, Wang YF, Liao L, Hilsenbeck SG, Brown PH, Xu J, Lee AVBMC cancerA moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis. BMC Cancer. 2011 Aug 25; 11:377.BMC Cancer2011-08-25T00:00:002011A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.21906370Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GBClinical proteomicsFunctional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics. 2011 Jul 08; 8(1):11.Clin Proteomics2011-07-08T00:00:002011Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer.Authorship 842532Authorship 846358Authorship 847209Authorship 850727Authorship 850971Authorship 851056Authorship 852159Authorship 852791Authorship 852894Authorship 853145Authorship 853264Authorship 854264Authorship 854394Authorship 854824Authorship 855304Authorship 855809Authorship 855867Authorship 856837Authorship 857609Authorship 859007Authorship 859284Authorship 859389Authorship 861379Authorship 861903Authorship 862743Authorship 862813Authorship 863763Authorship 863780Authorship 864378Authorship 865858Authorship 866256Authorship 867728Cancer Prevention ResearchPhase ib randomized, Double-blinded, Placebo- Controlled, Dose escalation study of polyphenon e in patients with barrett's esophagus. Cancer Prevention Research. 8:1131-1137.Phase ib randomized, Double-blinded, Placebo- Controlled, Dose escalation study of polyphenon e in patients with barrett's esophagusBreast Cancer Research and Treatment9-cis-retinoic acid suppresses mammary tumorigenesis in MMTV-ErbB2/Neu-transgenic mice. Breast Cancer Research and Treatment. 69:226.9-cis-retinoic acid suppresses mammary tumorigenesis in MMTV-ErbB2/Neu-transgenic miceClinical Cancer ResearchComprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Research. 21:1688-1698.Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancerFederation ProceedingsDevelopment of SJL T cell clones responsive to syngeneic lymphoma (RCS) and activated B cells. Federation Proceedings. 44:3237.Development of SJL T cell clones responsive to syngeneic lymphoma (RCS) and activated B cellsMolecular Cancer ResearchBlockade of AP-1 potentiates endocrine therapy and overcomes resistance. Molecular Cancer Research. 14:470-481.Blockade of AP-1 potentiates endocrine therapy and overcomes resistanceAnnals of OncologyLong-term effects of inhaled budesonide on screening-detected lung nodules. Annals of Oncology. 26:1025-1030.Long-term effects of inhaled budesonide on screening-detected lung nodulesBreast Cancer Research and TreatmentMetastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment. 141:375-384.Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancerSeminars in OncologyRetinoids and rexinoids in cancer prevention. Seminars in Oncology. 43:49-64.Retinoids and rexinoids in cancer preventionFederation ProceedingsFederation Proceedings. 43.Federation ProceedingsJournal of Oncology PracticeAmerican Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of Oncology Practice. 5:196-199.American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reductionBreast Cancer Research and TreatmentPhase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancerBreast DiseasesAdvances in targeted therapy for the prevention of breast cancer. Breast Diseases. 24:309-314.Advances in targeted therapy for the prevention of breast cancerBreast Cancer Research and TreatmentIdentification of proteins associated with the AP-1 transcription factor that are critical for breast cancer growth. Breast Cancer Research and Treatment. 69:234.Identification of proteins associated with the AP-1 transcription factor that are critical for breast cancer growthClinical Cancer ResearchMaternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer. Clinical Cancer Research. 22:5864-5875.Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancerOncologistOncologist. 21:4-6.OncologistJournal of Cellular BiochemistryCandidate biomarkers for application as intermediate end points of lung carcinogenesis. Journal of Cellular Biochemistry. 50:183-186.Candidate biomarkers for application as intermediate end points of lung carcinogenesisBreast Cancer Research and TreatmentOverexpression of cJun in breast cancer cells inhibits growth and induces cell death. Breast Cancer Research and Treatment. 69:273.Overexpression of cJun in breast cancer cells inhibits growth and induces cell deathEBioMedicineTissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerBreast DiseasesAnastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II). Breast Diseases. 25:214-216.Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II)Current Breast Cancer ReportsAdvances in preventive therapy for estrogen-receptor-negative breast cancer. Current Breast Cancer Reports. 6:96-109.Advances in preventive therapy for estrogen-receptor-negative breast cancerCancer Prevention, Screening, and Early Detection. 322-359.Cancer Prevention, Screening, and Early DetectionJournal of Human Nutrition and DieteticsEffects of a green tea extract, polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. Journal of Human Nutrition and Dietetics. Effects of a green tea extract, polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancerBreast DiseasesBreast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Breast Diseases. 16:73-74.Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulatorStrategies of hormonal prevention. 195-229.Strategies of hormonal preventionChemoprevention. ChemopreventionOncotargetThe SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression. Oncotarget. 7:13106-13121.The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expressionCancer Epidemiology, Biomarkers and PreventionAP-1 blockade in vivo suppresses development of mammary tumor im MMTV- erbB2 mice. Cancer Epidemiology, Biomarkers and Prevention. 14.AP-1 blockade in vivo suppresses development of mammary tumor im MMTV- erbB2 miceAnimal models for breast cancer prevention research. 497-526.Animal models for breast cancer prevention researchBreast Cancer Research and TreatmentRXR-selective retinoids function independently of RAR and PPARγ to inhibit breast cell growth. Breast Cancer Research and Treatment. 69:274.RXR-selective retinoids function independently of RAR and PPARγ to inhibit breast cell growthFrontiers in OncologyTargeted therapy for breast cancer prevention. Frontiers in Oncology. 3 SEP.Targeted therapy for breast cancer preventionCancer ResearchPhosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival. Cancer Research. 76:1942-1953.Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survivalBreast Cancer Research and TreatmentAnalysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment. 1-14.Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion10989982Brown PH, Lippman SMBreast cancer research and treatmentChemoprevention of breast cancer. Breast Cancer Res Treat. 2000 Jul; 62(1):1-17.Breast Cancer Res Treat2000-07-01T00:00:002000Chemoprevention of breast cancer.MAMTAKALIDASMAMTA KALIDAS12857KALIDAS, MAMTAClinical Assistant Professor11353774Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG, Brown PH, Fuqua SA, Osborne CKThe Journal of biological chemistryForkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem. 2001 Jul 27; 276(30):27907-12.J Biol Chem2001-05-15T00:00:002001Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions.14679152Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PHJournal of the National Cancer InstituteEffect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.J Natl Cancer Inst2003-12-17T00:00:002003Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.15378019Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, Brown PHOncogeneAP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity. Oncogene. 2004 Oct 28; 23(50):8238-46.Oncogene2004-10-28T00:00:002004AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity.15471505Kramer R, Brown PDrug safetyShould tamoxifen be used in breast cancer prevention? Drug Saf. 2004; 27(13):979-89.Drug Saf2004-01-01T00:00:002004Should tamoxifen be used in breast cancer prevention?16027729Lu C, Shen Q, DuPr? E, Kim H, Hilsenbeck S, Brown PHOncogenecFos is critical for MCF-7 breast cancer cell growth. Oncogene. 2005 Sep 29; 24(43):6516-24.Oncogene2005-09-29T00:00:002005cFos is critical for MCF-7 breast cancer cell growth.16469432Jang KS, Han HX, Paik SS, Brown PH, Kong GCancer lettersId-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. Cancer Lett. 2006 Dec 08; 244(2):203-10.Cancer Lett2006-02-08T00:00:002006Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer.16541309Seo HS, DeNardo DG, Jacquot Y, La?os I, Vidal DS, Zambrana CR, Leclercq G, Brown PHBreast cancer research and treatmentStimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat. 2006 Sep; 99(2):121-34.Breast Cancer Res Treat2006-03-16T00:00:002006Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha.16707456Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH, Lee AVCancer researchEpidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res. 2006 May 15; 66(10):5304-13.Cancer Res2006-05-15T00:00:002006Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.17257424Rajkumar L, Kittrell FS, Guzman RC, Brown PH, Nandi S, Medina DBreast cancer research : BCRHormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res. 2007; 9(1):R12.Breast Cancer Res2007-01-01T00:00:002007Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models.17947490Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, Hilsenbeck SG, Bissonnette RP, Lamph WW, Brown PHClinical cancer research : an official journal of the American Association for Cancer ResearchThe Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31.Clin Cancer Res2007-10-15T00:00:002007The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice.18362934Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, Lamph WW, Brown PHBritish journal of cancerThe rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer. 2008 Apr 22; 98(8):1380-8.Br J Cancer2008-03-25T00:00:002008The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.19861544Rodenberg JM, Brown PHCancer prevention research (Philadelphia, Pa.)A novel look into estrogen receptor-negative breast cancer prevention with the natural, multifunctional signal transduction inhibitor deguelin. Cancer Prev Res (Phila). 2009 Nov; 2(11):915-8.Cancer Prev Res (Phila)2009-10-27T00:00:002009A novel look into estrogen receptor-negative breast cancer prevention with the natural, multifunctional signal transduction inhibitor deguelin.19892666Brown PH, Viner JL, Brewster A, Heckman CJ, Hursting S, Johnson K, Mao JTCancer prevention research (Philadelphia, Pa.)Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila). 2009 Nov; 2(11):995-8.Cancer Prev Res (Phila)2009-11-01T00:00:002009Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research.20569503Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff RBreast cancer research : BCRProteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010; 12(3):R40.Breast Cancer Res2010-06-22T00:00:002010Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.20816505Johnson KA, Brown PHSeminars in oncologyDrug development for cancer chemoprevention: focus on molecular targets. Semin Oncol. 2010 Aug; 37(4):345-58.Semin Oncol2010-08-01T00:00:002010Drug development for cancer chemoprevention: focus on molecular targets.22053058Uray IP, Rodenberg JM, Bissonnette RP, Brown PH, Mancini MAMolecular pharmacologyCancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor ?-dependent mechanism. Mol Pharmacol. 2012 Feb; 81(2):228-38.Mol Pharmacol2011-11-03T00:00:002011Cancer-preventive rexinoid modulates neutral lipid contents of mammary epithelial cells through a peroxisome proliferator-activated receptor ?-dependent mechanism.22174377Hartmaier RJ, Richter AS, Gillihan RM, Sallit JZ, McGuire SE, Wang J, Lee AV, Osborne CK, O'Malley BW, Brown PH, Xu J, Skaar TC, Philips S, Rae JM, Azzouz F, Li L, Hayden J, Henry NL, Nguyen AT, Stearns V, Hayes DF, Flockhart DA, Oesterreich SMolecular endocrinology (Baltimore, Md.)A SNP in steroid receptor coactivator-1 disrupts a GSK3? phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol. 2012 Feb; 26(2):220-7.Mol Endocrinol2011-12-15T00:00:002011A SNP in steroid receptor coactivator-1 disrupts a GSK3? phosphorylation site and is associated with altered tamoxifen response in bone.22710573Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra LNature reviews. Gastroenterology & hepatologyHepatic stem cells and transforming growth factor ? in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2012 Sep; 9(9):530-8.Nat Rev Gastroenterol Hepatol2012-06-19T00:00:002012Hepatic stem cells and transforming growth factor ? in hepatocellular carcinoma.22771576Mohebati A, Knutson A, Zhou XK, Smith JJ, Brown PH, Dannenberg AJ, Szabo EContemporary clinical trialsA web-based screening and accrual strategy for a cancer prevention clinical trial in healthy smokers. Contemp Clin Trials. 2012 Sep; 33(5):942-8.Contemp Clin Trials2012-07-05T00:00:002012A web-based screening and accrual strategy for a cancer prevention clinical trial in healthy smokers.true1ProfessorProfessortrue1Professor EmeritusProfessor EmeritusD008325Disorders2044930.762535Mammary Neoplasms, ExperimentalD016588Chemicals & DrugsPhysiology1433620.821044Anticarcinogenic AgentsD018808Chemicals & Drugs1382460.900115Transcription Factor AP-1D013764Chemicals & Drugs481160.920052TetrahydronaphthalenesD001943Disorders1432156510.17611Breast NeoplasmsDepartment of MedicineDepartment of Molecular & Cellular BiologyMedicine-Hematology & OncologyMolecular & Cellular BiologyBaylor College of MedicineSUSANHILSENBECKSUSAN HILSENBECK0.000000000000000.000000000000003634HILSENBECK, SUSANProfessorDANIELMEDINADANIEL MEDINA0.000000000000000.000000000000002439MEDINA, DANIELProfessor Emeritus23682075Mohebati A, Milne GL, Zhou XK, Duffield-Lillico AJ, Boyle JO, Knutson A, Bosworth BP, Kingsley PJ, Marnett LJ, Brown PH, Akpa EG, Szabo E, Dannenberg AJCancer prevention research (Philadelphia, Pa.)Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers. Cancer Prev Res (Phila). 2013 Jul; 6(7):646-55.Cancer Prev Res (Phila)2013-05-16T00:00:002013Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.true1Clinical Assistant ProfessorClinical Assistant Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor22827973Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DLCancer prevention research (Philadelphia, Pa.)Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila). 2012 Sep; 5(9):1144-54.Cancer Prev Res (Phila)2012-07-24T00:00:002012Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.24535168Brown PNature reviews. Clinical oncologyPrevention: targeted therapy-anastrozole prevents breast cancer. Nat Rev Clin Oncol. 2014 Mar; 11(3):127-8.Nat Rev Clin Oncol2014-02-18T00:00:002014Prevention: targeted therapy-anastrozole prevents breast cancer.24961880Albanes D, Till C, Klein EA, Goodman PJ, Mondul AM, Weinstein SJ, Taylor PR, Parnes HL, Gaziano JM, Song X, Fleshner NE, Brown PH, Meyskens FL, Thompson IMCancer prevention research (Philadelphia, Pa.)Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila). 2014 Sep; 7(9):886-95.Cancer Prev Res (Phila)2014-06-24T00:00:002014Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).25178514Rechoum Y, Rovito D, Iacopetta D, Barone I, And? S, Weigel NL, O'Malley BW, Brown PH, Fuqua SABreast cancer research and treatmentAR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85.Breast Cancer Res Treat2014-09-02T00:00:002014AR collaborates with ERa in aromatase inhibitor-resistant breast cancer.